Filamin A interaction with the CXCR4 third intracellular loop regulates endocytosis and signaling of WT and WHIM-like receptors

Blood

Volumn 125, Issue 7, 2015, Pages 1116-1125

  Gómez Moutón, Concepción ^a   Fischer, Thierry ^a   Peregil, Rosa M ^a   Jiménez Baranda, Sonia ^a   Stossel, Thomas P ^b   Nakamura, Fumihiko ^b   Mañes, Santos ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BETA ARRESTIN; BINDING PROTEIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FILAMIN A; PROTEIN P160; RECEPTOR; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; WHIM LIKE RECEPTOR; CXCR4 PROTEIN, HUMAN; FILAMIN; PROTEIN BINDING;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL SURFACE; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; INTRACELLULAR LOOP; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN SECONDARY STRUCTURE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; WART, HYPOGAMMAGLOBULINEMIA, INFECTION, AND MYELOKATHEXIS SYNDROME; WILD TYPE; AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; GENETICS; HEK293 CELL LINE; IMMUNE DEFICIENCY; METABOLISM; MOLECULAR GENETICS; PROTEIN DOMAIN; TUMOR CELL LINE; VERRUCA VULGARIS;

AMINO ACID SEQUENCE; BINDING SITES; CELL LINE, TUMOR; ENDOCYTOSIS; FILAMINS; HEK293 CELLS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; WARTS;

EID: 84923272349     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-601807     Document Type: Article

References (61)

1. Bachelerie F. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome. Dis Markers. 2010;29(3-4): 189-198.
2. Balabanian K, Lagane B, Pablos JL, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2005;105(6):2449-2457.
3. Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003; 34(1):70-74.
4. Liu Q, Chen H, Ojode T, et al. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood. 2012;120(1):181-189.
5. Gulino AV, Moratto D, Sozzani S, et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood. 2004; 104(2):444-452.
6. Balabanian K, Levoye A, Klemm L, et al. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest. 2008;118(3):1074-1084.
7. Kawai T, Choi U, Cardwell L, et al. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. Blood. 2007; 109(1):78-84.
8. Walters KB, Green JM, Surfus JC, Yoo SK, Huttenlocher A. Live imaging of neutrophil motility in a zebrafish model of WHIM syndrome. Blood. 2010;116(15):2803-2811.
9. Balabanian K, Brotin E, Biajoux V, et al. Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood. 2012; 119(24):5722-5730.
10. Dale DC, Bolyard AA, Kelley ML, et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood. 2011; 118(18):4963-4966.
11. McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood. 2011; 118(18):4957-4962.
12. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta. 2007;1768(4): 952-963.
13. Roland J, Murphy BJ, Ahr B, et al. Role of the intracellular domains of CXCR4 in SDF-1- mediated signaling. Blood. 2003;101(2):399-406.
14. Haribabu B, Richardson RM, Fisher I, et al. Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem. 1997;272(45):28726-28731.
15. Signoret N, Rosenkilde MM, Klasse PJ, et al. Differential regulation of CXCR4 and CCR5 endocytosis. J Cell Sci. 1998;111(Pt 18): 2819-2830.
16. Orsini MJ, Parent JL, Mundell SJ, Marchese A, Benovic JL. Trafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization. J Biol Chem. 1999; 274(43):31076-31086.
17. Mueller W, Schütz D, Nagel F, Schulz S, Stumm R. Hierarchical organization of multi-site phosphorylation at the CXCR4 C terminus. PLoS ONE. 2013;8(5):e64975.
18. Marchese A, Trejo J. Ubiquitin-dependent regulation of G protein-coupled receptor trafficking and signaling. Cell Signal. 2013;25(3): 707-716.
19. Sun Y, Cheng Z, Ma L, Pei G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem. 2002;277(51):49212-49219.
20. Cheng ZJ, Zhao J, Sun Y, et al. beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem. 2000;275(4):2479-2485.
21. Lagane B, Chow KY, Balabanian K, et al. CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood. 2008;112(1):34-44.
22. Jiménez-Baranda S, Gómez-Moutón C, Rojas A, et al. Filamin-A regulates actin-dependent clustering of HIV receptors. Nat Cell Biol. 2007; 9(7):838-846.
23. Nakamura F, Stossel TP, Hartwig JH. The filamins: organizers of cell structure and function. Cell Adhes Migr. 2011;5(2):160-169.
24. Minsaas L, Planagumà J, Madziva M, et al. Filamin a binds to CCR2B and regulates its internalization. PLoS ONE. 2010;5(8):e12212.
25. Planagumà J, Minsaas L, Pons M, Myhren L, Garrido G, Aragay AM. Filamin A-hinge region 1-EGFP: a novel tool for tracking the cellular functions of filamin A in real-time. PLoS ONE. 2012;7(8):e40864.
26. Sampson LJ, Leyland ML, Dart C. Direct interaction between the actin-binding protein filamin-A and the inwardly rectifying potassium channel, Kir2.1. J Biol Chem. 2003;278(43): 41988-41997.
27. Seck T, Baron R, Horne WC. Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. J Biol Chem. 2003;278(12): 10408-10416.
28. Thelin WR, Chen Y, Gentzsch M, et al. Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. J Clin Invest. 2007;117(2):364-374.
29. Kim KM, Gainetdinov RR, Laporte SA, Caron MG, Barak LS. G protein-coupled receptor kinase regulates dopamine D3 receptor signaling by modulating the stability of a receptor-filamin-betaarrestin complex. A case of autoreceptor regulation. J Biol Chem. 2005;280(13): 12774-12780.
30. Kallikourdis M, Trovato AE, Anselmi F, et al. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse. Blood. 2013;122(5):666-673.
31. Mira E, Lacalle RA, Gonzá et al. A role for chemokine receptor transactivation in growth factor signaling. EMBO Rep. 2001;2(2):151-156.
32. García Lopez MA, Aguado Martínez A, Lamaze C, Martínez AC, Fischer T. Inhibition of dynamin prevents CCL2-mediated endocytosis of CCR2 and activation of ERK1/2. Cell Signal. 2009; 21(12):1748-1757.
33. Playford MP, Nurminen E, Pentikäinen OT, et al. Cystic fibrosis transmembrane conductance regulator interacts with multiple immunoglobulin domains of filamin A. J Biol Chem. 2010;285(22): 17156-17165.
34. van den Ent F, Löwe J. RF cloning: a restrictionfree method for inserting target genes into plasmids. J Biochem Biophys Methods. 2006; 67(1):67-74.
35. Nakamura F, Osborn TM, Hartemink CA, Hartwig JH, Stossel TP. Structural basis of filamin A functions. J Cell Biol. 2007;179(5):1011-1025.
36. Lacalle RA, Gómez-Moutón C, Barber DF, et al. PTEN regulates motility but not directionality during leukocyte chemotaxis. J Cell Sci. 2004; 117(Pt 25):6207-6215.
37. Tardíaguila M, Mira E, García-Cabezas MA, et al. CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res. 2013;73(14):4461-4473.
38. Page RC, Clark JG, Misra S. Structure of filamin A immunoglobulin-like repeat 10 from Homo sapiens. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011;67(Pt 8):871-876.
39. Razinia Z, Mäkelä T, Ylänne J, Calderwood DA. Filamins in mechanosensing and signaling. Annu Rev Biophys. 2012;41:227-246.
40. Zhao M, Discipio RG, Wimmer AG, Schraufstatter IU. Regulation of CXCR4-mediated nuclear translocation of extracellular signal-related kinases 1 and 2. Mol Pharmacol. 2006;69(1): 66-75.
41. Ehrlicher AJ, Nakamura F, Hartwig JH, Weitz DA, Stossel TP. Mechanical strain in actin networks regulates FilGAP and integrin binding to filamin A. Nature. 2011;478(7368):260-263.
42. Nakamura F, Song M, Hartwig JH, Stossel TP. Documentation and localization of force-mediated filamin A domain perturbations in moving cells. Nat Commun. 2014;5:4656.
43. Marchese A. Endocytic trafficking of chemokine receptors. Curr Opin Cell Biol. 2014;27:72-77.
44. Scott MG, Pierotti V, Storez H, et al. Cooperative regulation of extracellular signal-regulated kinase activation and cell shape change by filamin A and beta-arrestins. Mol Cell Biol. 2006;26(9): 3432-3445.
45. Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010; 330(6007):1066-1071.
46. Etzkorn M, Raschle T, Hagn F, et al. Cell-free expressed bacteriorhodopsin in different soluble membrane mimetics: biophysical properties and NMR accessibility. Structure. 2013;21(3): 394-401.
47. Ueda Y, Neel NF, Schutyser E, Raman D, Richmond A. Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Cancer Res. 2006;66(11):5665-5675.
48. Mellado M, Rodríguez-Frade JM, Mañes S, Martínez-A C. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol. 2001;19:397-421.
49. Percherancier Y, Berchiche YA, Slight I, et al. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem. 2005;280(11):9895-9903.
50. Zoughlami Y, Voermans C, Brussen K, et al. Regulation of CXCR4 conformation by the small GTPase Rac1: implications for HIV infection. Blood. 2012;119(9):2024-2032.
51. Kaur S, Fielding AB, Gassner G, Carter NJ, Royle SJ. An unmet actin requirement explains the mitotic inhibition of clathrin-mediated endocytosis. eLife. 2014;3:e00829.
52. Volovyk ZM, Wolf MJ, Prasad SV, Rockman HA. Agonist-stimulated beta-adrenergic receptor internalization requires dynamic cytoskeletal actin turnover. J Biol Chem. 2006;281(14):9773-9780.
53. Glogauer M, Arora P, Chou D, Janmey PA, Downey GP, McCulloch CA. The role of actinbinding protein 280 in integrin-dependent mechanoprotection. J Biol Chem. 1998;273(3): 1689-1698.
54. Savoy RM, Ghosh PM. The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it. Endocr Relat Cancer. 2013;20(6): R341-R356.
55. Gawecka JE, Griffiths GS, Ek-Rylander B, Ramos JW, Matter ML. R-Ras regulates migration through an interaction with filamin A in melanoma cells. PLoS ONE. 2010;5(6):e11269.
56. Ai J, Huang H, Lv X, et al. FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell Physiol Biochem. 2011;27(3-4):207-216.
57. Jiang X, Yue J, Lu H, et al. Inhibition of filamin-A reduces cancer metastatic potential. Int J Biol Sci. 2013;9(1):67-77.
58. Tian HM, Liu XH, Han W, Zhao LL, Yuan B, Yuan CJ. Differential expression of filamin A and its clinical significance in breast cancer. Oncol Lett. 2013;6(3):681-686.
59. Sun GG, Lu YF, Cheng YJ, Hu WN. Absent expression of FLNA is correlated with poor prognosis of nasopharyngeal cancer. Tumour Biol. 2014;35(4):2967-2974.
60. Diaz GA. Released on a WHIM. Blood. 2011; 118(18):4764-4765.
61. McDermott DH, Liu Q, Velez D, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014;123(15):2308-2316.